UK Markets close in 1 hr 10 mins

Eurobio Scientific Société anonyme (ALERS.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
20.50+0.50 (+2.50%)
As of 03:58PM CET. Market open.
Full screen
Previous close20.00
Open20.24
Bid0.00 x 0
Ask0.00 x 0
Day's range20.24 - 20.98
52-week range16.05 - 23.70
Volume38,602
Avg. volume37,289
Market cap232.536M
Beta (5Y monthly)-0.75
PE ratio (TTM)3.15
EPS (TTM)6.52
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Eurobio Scientific Launches the First Pcr Test Allowing Simultaneous Sars-Cov-2 Virus Screening and Detection of the Delta and Omicron Variants in a Single Reaction

    EUROBIO SCIENTIFIC LAUNCHES THE FIRST PCR TEST ALLOWING SIMULTANEOUS SARS-COV-2 VIRUS SCREENING AND DETECTION OF THE DELTA AND OMICRON VARIANTS IN A SINGLE REACTION Test to detect the presence of the Omicron variant and type the Delta variant during routine COVID screeningFirst test with multiplex technology requiring only one reactionPCR result obtained in just 45 minutesProprietary test available in RUO format Paris, November 30, 2021 – 5:45pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME e

  • Globe Newswire

    Eurobio Scientific Makes a Minority Investment in Usense, a Start-Up Developping a Mobile in Vitro Medical Device for Urianalysis

    EUROBIO SCIENTIFIC MAKES A MINORITY INVESTMENT IN USENSE, A START-UP DEVELOPPING A MOBILE IN VITRO MEDICAL DEVICE FOR URIANALYSIS With this investment, the Group strengthens its offer in point of care medical biology and positions itself in the digitalization of diagnostics Paris, November 23, 2021 – 6:15pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in the field of specialty in vitro medical diagnostics, announces today that it made a minority investment i

  • Globe Newswire

    EUROBIO Scientific : 2021 HALF-YEAR EARNINGS

    2021 HALF-YEAR EARNINGS EBITDA up +110% to €42.5mNet cash of €60.4mCOVID accelerating the Group’s longstanding activities and strategic development Paris, October 12, 2021 – 5:35pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French in vitro medical diagnostics and life sciences group, is today reporting its half-year earnings at June 30, 20211. Eurobio Scientific’s first-half earnings reflect another strong level of revenues, with €95.6m, across its COVID and non-COVID